From the University of Texas Health Science Center, San Antonio, TX (MAS); Retinal Consultants of Arizona, Phoenix, AZ, and Keck School of Medicine, University of Southern California, Los Angeles (PUD); Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, and New Jersey Retina, New Brunswick, NJ (HFF); Associated Retinal Consultants, Royal Oak, MI (AC); and Allergan plc, Irvine, CA (JM).
This study was presented in part at the 1st Retina World Congress on February 26, 2017, in Fort Lauderdale, FL.
This study was sponsored by Allergan plc, Dublin, Ireland. The study sponsor was involved in the study design, provided funding for medical writing and editorial assistance in the manuscript development, and approved the manuscript submission. A contract research organization, PRA Health Sciences (Lenexa, KS), was responsible for data management and performed the statistical analysis of the data. Howard Christian, PhD (Mediscinz Communications Limited, Mount Pisa, New Zealand), and Kate Ivins, PhD (Evidence Scientific Solutions, Philadelphia, PA), provided medical writing and editorial assistance with the manuscript preparation.
Dr. Singer is a consultant for Aerpio, Alimera, Allergan, Ampio, Genentech, and Santen and has received research grant support from Acucela, Aerpio, Alcon, Alimera, Allergan, Ampio, Genentech, Ophthotech, and Regeneron. Dr. Dugel is a consultant for Abbott/AMO, Acucela, Aerpio, Alcon, Alimera, Allergan, Annidis, ArcticAx, Avalanche, Clearside, Digisight, DOSE Medical, Genentech, Lutronic, Lux BioScience, Novartis, OD-OS, Omeros, Ophthotech, Opthea, Optovue, ORA, Regeneron, Roche, Pentavision, Stealth, Thrombogenics, and TopCon and is a minor stockholder of Aerpio, Alimera, Annidis, Neurotech, Ophthotech, and TrueVision. Dr. Fine is a consultant for Alimera, Allergan, Genentech, and Regeneron and has received research grant support from Alcon, Alimera, Allergan, Genentech, GSK, and Regeneron. Dr. Capone is a consultant for and/or has received research funding from Acucela, Allergan, Novartis, Spark, and Synergetics; has a patent with Retinal Solutions; and owns stock in FocusROP and Retinal Solutions. Dr. Maltman is an employee of Allergan.
The authors would like to acknowledge the REINFORCE Study Group principal investigators and sites: David G. Callanan, MD (Arlington, TX); Richard Chace, MD (Portsmouth, NH); Sanford Chen, MD (Santa Ana, CA); Pravin U. Dugel, MD (Phoenix, AZ); Lisa J. Faia, MD (Royal Oak, MI); Philip Ferrone, MD (Great Neck, NY); Howard F. Fine, MD (New Brunswick, NJ); Victor H. Gonzalez, MD (McAllen, TX); Nancy M. Holekamp, MD (Chesterfield, MO); J. Michael Jumper, MD (San Francisco, CA); Mathew W. MacCumber, MD, PhD (Oak Park, IL); Raj K. Maturi, MD (Indianapolis, IN); Sonia Mehta, MD (Philadelphia, PA); Mark E. Patron, MD (Denver, CO); Tushar M. Ranchod, MD (Walnut Creek, CA); Michael A. Singer, MD (San Antonio, TX); and Scott R. Sneed, MD (Traverse City, MI).
Address correspondence to Michael Singer, MD, 9157 Huebner Road, San Antonio, TX 78240; email:
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International (https://creativecommons.org/licenses/by/4.0). This license allows users to copy and distribute, to remix, transform, and build upon the article, for any purpose, even commercially, provided the author is attributed and is not represented as endorsing the use made of the work.